´â¼­Åµ
  ÏÀʸ°ìÍ÷¡¡Ê¬³äɽ¼¨¡¡2¡¿10
´Ê°×¸¡º÷
¡¡   
¡¡
¥ê¥¹¥È¹¹¿·¡§2008/03/01(Sat) 05:13 JST
¹¹¿·¤Ï½ªÎ»¤·¤Þ¤·¤¿ ºÇ¿·¤Ï ʬ³äɽ¼¨¡¡1¡¿10

£±ÊÇɽ¼¨¤Ï¡¡¤³¤Á¤é¡£¡¡¡¡¡¡ ¤³¤Á¤é¤â¡¡ÊIJͽñ¸Ë¡¦¥ê¥¹¥È°ìÍ÷


¼ýÏ¿ÏÀʸ¡¡Á´[3889]·ïÃæ¡¡¥¢¥ë¥Õ¥¡¥Ù¥Ã¥È½ç[400]·ï

1¡¿10¤Ø¡¡ 2¡¿10¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡
¡¡
¡¡ÏÀʸ̾¶èʬ
C·¿ËýÀ­´Î±ê¤Î²¹Ç®ÎÅË¡¤Ë¤è¤ë´ÎÁÈ¿¥Æâ°äÅÁ»Òȯ¸½¤ÎÊѲ½ ¢¡¡ú²¹Ç®¼£ÎÅÆÃÀß Â¾
C·¿ËýÀ­´Î±ê·Ð²áÃæ¤Ëȯ¾É¤·¤¿ç¹°­À­¥ê¥ó¥Ñ¼ð¤Î1˶¸¡Îã ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
C·¿ËýÀ­´Î±ê¸¦µæ¤Î¿ÊÊâ¤ÈŸ˾¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡´Î±ê ¾
Danenberg Tumor ProfileË¡¤Ë¤è¤ëÂçIJ´â¤Ë¤ª¤±¤ëTS¤ª¤è¤ÓDPD mRNAȯ¸½Î̤θ¡Æ¤ ¢¡ÂçIJ´â ¾
Degradable starch microspheres (DSM) Ê»ÍÑ´ÎÆ°Ì®²½³ØºÉÀòÎÅË¡ (DSM-TACE) ¤¬Ãø¸ú¤·¤¿, ²¼ÂçÀÅÌ®¤ª¤è¤ÓÌçÌ®¼ðáçºÉÀò¤ò¤È¤â¤Ê¤¦¤Ó¤Þ¤ó·¿´ÎºÙ˦´â¤Î1Îã ¢¡´Î¡´â ¾
DIC ¿ÇÃÇ´ð½à¤ÎÊÑÁ«¡¡¡¡¡¦¡¦¡¦DIC¤Î¿ÇÃÇ DlC¤Î³µÇ°¡¦ÄêµÁ DIC¤Î³µÇ°¡¦¿ÇÃǤÎÊÑÁ«¡¡¿ÇÃÇ´ð½à¤ÎÈæ³Ó¡¡¡¦¡¦ ¢¡DIC ¾
DIC¤Ë¤ª¤±¤ë¿·¤·¤¤¹³¶Å¸ÇÌô¤Î»È¤¤Ê¬¤±¡¡¡¦¡¦¡¦Äãʬ»Òheparin ºîÍѵ¡½ø¡¡ÌôÍýºîÍÑ¡¡ ¥Ø¥Ñ¥ê¥Î¥¤¥É¡¡¡¦¡¦ ¢¡DIC ¾
DIC¤Î¸¡ºº¤Îή¤ì¤ÈÆÉ¤ßÊý¡¡¡¦¡¦¡¦DIC¤Î¸¡ºº ·ì¾®ÈÄ¿ô ¥×¥í¥È¥í¥ó¥Ó¥ó»þ´ÖÈæ ·ìÞù¥Õ¥£¥Ö¥ê¥Î¥²¥óÃÍ¡¡FDP¡¡·ì¾®ÈÄ¿ô¡¦¡¦ ¢¡DIC ¾
DIC¤òʻȯ¤·MTX/5-FU¸òÂåÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô°ß´â¤Î1Îã ¢¡DIC ¾
 ¢¡3729²½³ØÎÅË¡ ¾
DlC¤Îɰø¤ÈÎ×¾²ÉÂÂ֤οÍÍÀ­¡¡¡¦¡¦¡¦DIC¤Îɰø¤ÈÎ×¾²¾É¾õ¤Î´ØÏ¢¡¡ ´ðÁüÀ´µÊ̤ÎDICȯ¾Éµ¡½ø¡¡ ¡¡ÇÔ·ì¾É¡¡¸Ç·Á¼ðáç¡¡µÞ¡¦¡¦ ¢¡DIC ¾
DlC¼£ÎŤδðËÜ¡¡¡Ý DlC¤Î¼£ÎÅ¡¡¡¦¡¦¡¦¹³¶Å¸ÇÎÅË¡ heparin À®ÃÁÇòʬ²ò¹ÚÁÇÁ˳²Ìô FOY ¹³ÀþÍÏÎÅË¡¡¡ Êä½¼¡¦¡¦ ¢¡DIC ¾
DMpCÎÅË¡¤¬°Ý»ýÎÅË¡¤È¤·¤ÆÍ­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹ÔºÆÈ¯Æý´â¤Î1Îã ¢¡Æý´â ¾
DNA¥Á¥Ã¥×¤òÍѤ¤¤¿Ê¢ËìÇżï¿ÇÃǤΤ¿¤á¤Î¿·µ¬¥Þ¡¼¥«¡¼¤Îõº÷ ¢¡´âÀ­Ê¢Ëì±ê ¾
DNA¥È¥Ý¥¤¥½¥á¥é¡¼¥¼Á˳²³èÀ­¤Î¸¡Äê¡¡¡¦¡¦¡¦¹³¤¬¤óºÞõº÷¤Î¥Ð¡¼¥Á¥ã¥ë¸¦µæ½ê¡¼Ê¸Éô¾Ê¤¬¤óÆÃÄêÎΰ踦µæ¤Ë¤ª¤±¤ë¹³¤¬¤óºÞ¥¹¥¯¥ê¡¼¥Ë¥ó¥°¡¼¡¦¡¦ ¢¡²½³ØÎÅË¡ ¾
DNA¥á¥Á¥ë²½¤È´â-²½³ØÎÅË¡¤ÎɸŪ¤È¤·¤Æ-30-13
Docetaxel (TXT) Medroxyprogesterone Acetate (MPA)¤ÎÊ»ÍѤˤè¤ê´°Á´´²²ò¤¬ÆÀ¤é¤ì¤¿Æý´â½Ñ¸å¿ȯÀ­ÇÙž°Ü¤Î1Îã ¢¡Æý´â ¾
Docetaxel(TXT)¤Î½ÑÁ°Æ°ÃíÎÅË¡¤òÃæ¿´¤È¤·¤¿½¸³ØÅª¼£ÎŤ¬ÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÆý´â¤Î1Îã ¢¡Æý´â ¾
Docetaxel+5'-DFURÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿ºÆÈ¯°ß´â¤Î1Îã ¢¡°ß´â ¾
Docetaxel+PrednisoloneÎÅË¡¤¬Ãø¸ú¤·¼ðáçÇ®¤¬·Ú²÷¤·¤¿¥Û¥ë¥â¥óÄñ¹³À­Á°Î©Á£´â¤Î1Îã33-06
Docetaxel+TS-1Ê»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Â¿È¯À­¹üž°Ü,Ê¢ËìÇżï¤òȼ¤¦»Ä°ß´â¤Î1Îã ¢¡¹üž°Ü ¾
Docetaxel,Cisplatin,5-FU Regimen2¥¯¡¼¥ë¸å¤ËÊü¼ÍÀþ¾È¼ÍÎÅË¡¤òÊ»ÍѤ·¤¿²¼°öƬ´â4¾ÉÎã ¢¡°öƬ´â ¾
Docetaxel,Cisplatin,5-FU,l-Leucovorin¤ËÁÕ¸ú¤·¤¿Ãæ°öƬ´âÇÙž°Ü¾ÉÎã ¢¡°öƬ´â ¾
Docetaxel,Cisplatin,5-FU,Levofolinate¤òÍѤ¤¤¿²½³ØÎÅË¡¤ÇCR¤òÆÀ¤¿²¼°öƬ´â¤Î1Îã29-10
Docetaxel,Ifosfamide,Cisplatin¤ËÁÕ¸ú¤·¤¿¶É½ê¿Ê¹ÔÃæ°öƬ´âÎã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
Docetaxel/CyclophosphamideÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿Æý´â½Ñ¸å¿ȯÇÙž°Ü¤Î1Îã ¢¡¶»Éô ¾
Docetaxel/TS-1Ê»ÍÑÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿´âÀ­¥ê¥ó¥Ñ´É¾É¤òȼ¤¦ÀÚ½üÉÔǽ¿Ê¹Ô°ß´â¤Î1Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
Docetaxel¡ÜDoxifluridine²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿°ß´âÈéɿž°Ü¤Î1Îã ¢¡°ß´â ¾
Docetaxel¤¬Ãø¸ú¤·¤¿¹¢Æ¬´âÇÙž°Ü¾ÉÎã ¢¡¹¢Æ¬´â ¾
Docetaxel¤Ë¤è¤ëNeoadjuvant Chemotherapy¸åÊü¼ÍÀþ¼£ÎŤÇÀ©¸æ¤µ¤ì¤¿²¼°öƬ¸åÊÉ´â¾ÉÎã ¢¡°öƬ´â ¾
Docetaxel¤Î·ìÃæ,Ê¢¿åÃæ¤ÎÌôʪưÂÖ¤ò¸¡Æ¤¤·¤¿°ß´â¤Î1Îã ¢¡°ß´â ¾
Docetaxel¤ÎĶÁªÂòŪưÃíÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿¿Ê¹Ô²¼°öƬ´â¤Î1Îã ¢¡°öƬ´â ¾
Docetaxel¤òÊ»ÍѤ·¤¿¿©Æ»´â¤ËÂФ¹¤ë²½³ØÊü¼ÍÀþÎÅË¡ ¢¡Êü¼ÍÀþ´ØÏ¢ ¾
 ¢¡3731²½³ØÎÅË¡ ¾
Docetaxel²½³ØÎÅË¡¤¬ÁÕ¸ú¤·ÀÚ½ü²Äǽ¤È¤Ê¤Ã¤¿stage IV°ß´â¤Î1Îã39-01
Docetaxel´ÎưÃí¤ÈTrastuzumabÀÅÃí¤Ë¤è¤ëÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿Æý´â´Îž°Ü¤Î1Îã31-09
DocetaxelưÃíÊ»ÍÑÊü¼ÍÀþÎÅË¡¤ÇÎɹ¥¤Ê·Ð²á¤ò¤È¤Ã¤¿91ºÐ¾å³Ü´â¾ÉÎã ¢¡¾å³Ü´â ¾
Doxifluridine(5'-DFUR),Cyclophosphamide(CPA),Medroxyprogesteroneacetate(MPA)¤ÈPamidronate¡¡Disodium¤ÎÊ»ÍѤˤè¤êµÞ®¤Ë²þÁ±¤·¤¿Æý´â¹üž°Ü¤Î1Îã ¢¡¹üž°Ü ¾
Doxorubicin(adriamycin)¤ò°ÂÁ´¤Ë»ÈÍѤ·¤¨¤¿Marfan¾É¸õ·²¹çÊ»°Û»þξ¦Æý´â¤Î1Îã ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
DPC¤È¤¬¤ó¿ÇÎÅ¡¡¡¦¡¦¡¦Êñ³çɾ²Á¤Î¿ÇÃÇ·²Ê¬Îà¡¡ °åÎÅÈñ¤Î»ÙʧÊýË¡¡¡ ¼ÂºÝ¤Î»»ÄêÎã¡¡ ¸½ºß¤ÎÊñ³ç»Ùʧ¤¤¤Ç¤ÎÌ䡦¡¦ ¢¡À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾
DPC¤È¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¡¡¡¦¡¦¡¦¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î¸úÍÑ¡¡ ´â¿ÇÎŤˤª¤±¤ë¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î±¿ÍÑ¡¡ ¥¯¥ê¥Æ¥£¥«¥ë¥Ñ¥¹¤Î¡¦¡¦ ¢¡À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾
DPC»Ü¹Ô¤Ë¤è¤ë´â²½³ØÎÅË¡¤ÎÊѲ½¡¡¡¦¡¦¡¦Êñ³çÀè¿Ê°åÎÅ¥»¥ó¥¿¡¼¤Ø¤Î½¸Ãæ²½¡¡Á´¹ñ82»ÜÀß ¾Ã²½´ï´â¡¡ Æý´â ¹Í»¡¡¦¡¦ ¢¡À©ÅÙ¡¦Ë¡Î§¡¦Åý·× ¾
Dukes'CÂçIJ´â¤ËÂФ¹¤ëͽËÉŪ´Îư̮²½³ØÎÅË¡¤ÎÀ®ÀÓ-¸¶È¯Áã¤ÎTS,DPD,p53¤ª¤è¤ÓOPRTȯ¸½¤È¤Î´Ø·¸- ¢¡ÂçIJ´â ¾
Dxtran magnetite(DM)γ»Ò¤òÍѤ¤¤ëÁÈ¿¥ÆâͶƳ²Ã²¹Ë¡¤Î´ðÁäÈÎ×¾²±þÍÑ ¢¡18-Supplement ¾
Dynamic MRI¤¬Í­ÍѤǤ¢¤Ã¤¿ÀøºßÀ­Æý´â¤Î1Îã ¢¡Æý´â ¾
EBM¡¦(Evidence-Based Medicine) ¤È¤Ï¡© ¢¡DIC ¾
EBM¤Ë´ð¤Å¤¤¤¿Å¾°ÜÀ­Ç¾¼ðáç¤Î¼£ÎÅ¡¡¡¦¡¦¡¦ÉÑÅÙ¡¡ ͽ¸å°ø»Ò ñȯÀ­¼ðáç¤ËÂФ¹¤ë¼£ÎÅ¡¡ ¡¡³°²Ê¼ê½Ñ¡ÜÁ´Ç¾¾È¼Í¡¡Äê°ÌÊü¼ÍÀþ¾È¼Íñ¡¦¡¦ ¢¡Ç¾¼ðáç ¾
EBM¤Ë´ð¤Å¤¯°ßÄÙáç¿ÇÎÅ¥¬¥¤¥É¥é¥¤¥ó¡¡¡¦¡¦¡¦¤Ï¤¸¤á¤Ë¡¡¡¡ ­µ.Evidence-based medicine(EBM)¤È°ßÄÙáç¿ÇÎÅ¡¦¡¦62-07
ECÎÅË¡(Epirubicin,Cyclophosphamide),Taxanes,Trastuzumab¼£ÎŸå¤ËUFT¤ÈCPAÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿HER2ÍÛÀ­ºÆÈ¯Æý´â(ÇÙž°Ü)¤Î1Îã ¢¡Æý´â ¾
Electrofusion¤Ë¤è¤ë¼ù¾õºÙ˦¤È¥Ò¥È°ß´âºÙ˦¤ÎÍ»¹çºÙ˦¤ÎºîÀ½¤ÈCTLͶƳ¤Î»î¤ß ¢¡°ß´â ¾
Electrolyte depletion syndrome¤òÄ褷¤¿Ä¾Ä²å°ÌÓ¼ðáç¤Î1Îã39-02
EMR¤ÎŬ±þ¤È¼£ÎÅÀ®ÀÓ¡¡¡¦¡¦¡¦¿ÇÃÇ¡¦¼£Îŵ»½Ñ¹ÖºÂ¡¡¡¡°ß´â¤ÎEMR¡ÝÂè1²ó ¡¡¡¡ ¡¡1.ESDŬ±þÉÂÊѤÎÁªÂò¡¡ ¡¡¡¦¡¦ ¢¡°ß´â ¾
Endometriosis¤òÇØ·Ê¤È¤·¤¿ÍñÁã Carcinosarcoma¤Î1¾ÉÎã ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
EORTC QOLÄ´ººÉ¼°ß´â´µ¼ÔÍѥ⥸¥å¡¼¥ëSTO22(ÆüËܸìÈÇ)¤Î³«È¯ ¢¡°ß´â ¾
Estrogen Receptor¤ª¤è¤ÓProgesterone Receptor¬Äê¤Ë¤ª¤±¤ëDextran Charcoal Method¤ÈEnzyme Immunoassay´ÖÉÔ°ìÃ×°ø»Ò¤Î¸¡Æ¤ ¢¡Æý´â ¾
Etoposide,Ara-C¾¯ÎÌ»ý³ÅÀÅ©ÎÅË¡¤ËMitoxantrone¤ò²Ã¤¨¤¿MEtAÎÅË¡¤Ë¤è¤ê´²²ò¤òÆÀ¤¿De Novo AML with Trilineage Myelodysplasia(AML/TMDS)¤Î5¾ÉÎã ¢¡Çò·ìÉ ¾
Etoposide,Ifosfamide,Nedaplatin¤Ë¤è¤ë3ºÞÊ»ÍѲ½³ØÎÅË¡¤¬Ãø¸ú¤·¤¿¶»Á£´â¤Î1Îã ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
Etoposide¤Ë¤è¤ë²áÉÒÈ¿±þ¤Î1Îã¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡ÍñÁã´â ¾
EtoposideÆâÉþ¤¬Ãø¸ú¤·¤¿°ß¸¶È¯¤ÓÌ¡À­ÂçºÙ˦·¿BºÙ˦¥ê¥ó¥Ñ¼ð¤Î½Ñ¸åºÆÈ¯¤Î1Îã ¢¡£³·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
EUS FNA¤Ç¿ÇÃǤ·, ưÃí²½³ØÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿AFP»ºÀ¸ç¹Á£Ë¼ºÙ˦´â¤Î1Îã ¢¡9·î£²½µ¡Ê£¹Æü¡Ë ¾
EUS, US¡¡¡¦¡¦¡¦EUS¤Ë¤è¤ëç¹´â¤ÎÁá´ü¿ÇÃÇ¡¿EUS¤Ë¤è¤ë¾¼À´µ¤È¤Î´ÕÊÌ¿ÇÃÇ¡¿EUS¤Ë¤è¤ëç¹´â¤ÎÉ´ü¿ÇÃÇ¡¿¡¦¡¦76
Evaluation of Cell Viability by Double-staining Fluorescence Assay29-11
Evidence¤Ë´ð¤Å¤¯È󾮺Ù˦ÇÙ´â½Ñ¸åÊä½õÎÅË¡¤ÎÍ­ÍÑÀ­ ¢¡Êü¼ÍÀþ´ØÏ¢ ¾
EwingÆù¼ð¡¡¡¦¡¦¡¦Èæ³ÓŪ¤Þ¤ì¤Ê¼ðáç¤Î¿ÇÃǤȼ£ÎÅ­¶¡¦¡¦ ¢¡Æù¼ð ¾
EwingÆù¼ð¤Î¼£ÎÅ¡¡¡¦¡¦¡¦²¤ÊƤˤª¤±¤ëɸ½àŪ²½³ØÎÅË¡¤È¼£ÎÅÀ®ÀÓ ¶É½êÎÅË¡¡Ê³°²ÊÎÅË¡¡¦Êü¼ÍÀþÎÅË¡¡Ë¡¡ ¤ï¤¬¹ñ¤Ë¤ª¡¦¡¦ ¢¡£´·îÂ裱½µ¡§£²Æü¡ÊÅÚ¡Ë Â¾
Examestane¤¬Ãø¸ú¤·¤¿ºÆÈ¯Æý´â¤Î1Îã ¢¡ÇÙ´â ¾
Exemestane¤¬Í­¸ú¤Ç¤¢¤Ã¤¿AnastrozoleÂÑÀ­Æý´â¤Î1Îã31-12
Exemestane¤Î·ò¾ïÊķиå½÷À­¤Ë¤ª¤±¤ëñ²óÅêÍ¿»î¸³ ¢¡Æý´â ¾
Exemestane¤Î·ò¾ïÊķиå½÷À­¤Ë¤ª¤±¤ëÈ¿Éü·Ð¸ýÅêÍ¿»î¸³ ¢¡Æý´â ¾
ExemestaneñÆÈÅêÍ¿¤Ë¤è¤êÃø¸ú¤òÆÀ¤¿ÇÙ¡¦¶»Ë잰ܤòȼ¤Ã¤¿¹âÎð¼Ô¿Ê¹ÔÆý´â¤Î1Îã ¢¡Æý´â ¾
FAP¤ª¤è¤ÓGemcitabine+UFT¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹ÔÃÀǹ´â¤Î1Îã ¢¡ÃÀÆ»´â ¾
FDG-PET ¤Ë¤è¤ëƬðôÉô¼ðáç ¿ÇÃÇ¡¡¡¦¡¦¡¦PET¸¡ºº¤Î¼ÂºÝ ƬðôÉô´â¿ÇÃÇ ¹Ã¾õÁ£´â¿ÇÃÇ¡¦¡¦ ¢¡Æ¬ðôÉô ¾
FDG-PET, Receptor Imaging76
FDG-PET¤¬°ì²áÀ­´ÎưÃíºÉÀòÎÅË¡¤Î¸ú²ÌȽÄê¤ËÍ­ÍѤȻפï¤ì¤¿Ä¾Ä²´â´Îž°Ü¤Î1Îã ¢¡Å¾°ÜÀ­´Î¡´â ¾
FDG-PET¤¬¿ÇÃǤËÍ­ÍѤǤ¢¤Ã¤¿°­À­Ê¢ËìÃæÈé¼ð¤Î1Îã ¢¡£¸·î£±Æü ¾
FDG-PET¤Ç½¸ÀÑж¿Ê¤òǧ¤á¤¿¿©Æ»¸¶È¯gastrointestinal stromal tumor (GIST) ¤Î1Îã ¢¡GIST ¾
FDG-PET¤Ç¿ÇÃǤ·¤¨¤¿¸¶°øÉÂÁãÉÔÌÀ¤Î·ìÀ¶¼ðáç¥Þ¡¼¥«¡¼¹âÃͤòÀè¹Ô¤È¤·¤¿Æý´â½Ñ¸åÍñÁ㞰ܤÎ1Îã ¢¡8·îÂè2½µ(5Æü¡Ë ¾
FDG-PET¤òÍý²ò¤¹¤ë¤¿¤á¤Î´ðÁÃÃμ±¡¡¡¦¡¦¡¦¥Ú¥Ã¥È¤È¤Ï¡¡ PET¸¡ºº¤ÎÌò³ä¡¡ ÈïÇú¡¡ º£¸å¤Î²ÝÂê¤ÈŸ˾¡¡Ä¹½ê¡¡¼åÅÀ¡¦¡¦ ¢¡²èÁü¿ÇÃÇ Â¾
FDG-PET¸¡ºº¤Ç¶¯¤¤½¸ÀÑÁü¤ò¼¨¤·¤¿»ÒµÜÊ¿³ê¶Ú¼ð¤Î1Îã ¢¡9·îÂ裱½µ¡Ê1Æü¡Ë ¾
FDG-PET¸¡ºº¤Ë¤è¤ë¾Ã²½´ï´â¤Î¿ÇÃÇ¡¡¡¦¡¦¡¦¾Ã²½´ï´â¤Ë¤ª¤±¤ëFDG-PET¸¡ºº¤ÎÎ×¾²ÅªÍ­ÍÑÀ­¡¡ ¡¡¥ê¥ó¥ÑÀáž°Ü¿ÇÃÇ¡¡±ó³Öž°Ü¿ÇÃÇ¡¡¡¦¡¦ ¢¡²èÁü¿ÇÃÇ Â¾
FEC(100)¤ÈWeekly Paclitaxel¿ë¼¡ÅêͿˡ¤¬ÁÕ¸ú¤·¤¿¿Ê¹ÔÆý´â¤Î1Îã ¢¡2·î ¾
Fixed Recurrent Tumor ¤ËÂФ¹¤ëÀç¹ü¹çÊ»¹üÈׯâ¡Á´Å¦½Ñ ¢¡£²·îÂ裴½µ¡§£²£µÆü¡Ê¶â¡Ë ¾
FLIEÄ´ººÉ¼ÆüËܸìVersion¤Î³«È¯¡¡¡¦¡¦¡¦¡¦¡¦29-02
Folinate¡¦Tegafur¡¦Uracil(UFT/LV)ÎÅË¡¤¬ÁÕ¸ú¤·¤¿¿Ê¹Ô¡¦ºÆÈ¯ÂçIJ´â¤Î1Îã ¢¡ÂçIJ´â ¾
Fourth-Line Therapy¤È¤·¤ÆBi-weekly CPT-11/CDDPÊ»ÍѲ½³ØÎÅË¡¤¬Í­¸ú¤Ç¤¢¤Ã¤¿°ß´â´Îž°ÜºÆÈ¯¤Î1Îã ¢¡°ß´â ¾
FPÎÅË¡¤Ë³¤¤¤ÆTS-1¤ÎÅêÍ¿¤Ë¤è¤Ã¤Æ½Ñ¸åÎɹ¥¤Ê·Ð²á¤ò¼¨¤·¤Æ¤¤¤ë¹âÅٿʹ԰ߴâ¤Î1Îã ¢¡°ß´â ¾
FU·Ï¹³´âºÞ¤Ë¤ª¤±¤ë´ÊÊØ¤Ê¥ª¡¼¥À¡¼¥á¥¤¥É¼£ÎŤòÌܻؤ·¤¿Ç¢Ã楦¥é¥·¥ë¤ª¤è¤Ó¥×¥é¥º¥Þ5-FU¥¯¥ê¥¢¥é¥ó¥¹¤ÎÊ»ÍѬÄê ¢¡²½³ØÎÅË¡ ¾
G-CSF¤ò»ºÀ¸¤·¡¤Á£´â¤Ø¤Î°­À­Å¾²½¤òȼ¤Ã¤¿½Ä³Ö´ñ·Á¼ð¤Î1Îã ¢¡ÇÙ´â ¾
G-CSF»ºÀ¸ ¿©Æ»¾®ºÙ˦·¿Ì¤Ê¬²½´â¤Î1Îã ¢¡¿©Æ»´â ¾
G-CSFÅêÍ¿Ãæ¤Ë¹âÇ®¤ª¤è¤ÓCRP¹âÃͤòǧ¤á¤¿°­À­¥ê¥ó¥Ñ¼ð¤Î2Îã ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Gastrointestinal Stromal Tumor ¢¡GIST ¾
Gastrointestinal Stromal Tumor(GIST)¤ò½ä¤ëºÇ¶á¤Î¿ÊÊâ ¢¡GIST ¾
Gastrointestinal Stromal Tumors¤Îʬ»ÒɸŪ¼£ÎÅ-ʬ»Ò¿ÇÃǤ«¤éʬ»ÒɸŪ¼£ÎŤޤÇ- ¢¡GIST ¾
GDA-¥³¥¤¥ë¸ÇÄêË¡¤Ë¤ª¤±¤ë¦¹¦ÉÕ¤­¥«¥Æ¡¼¥Æ¥ë¤òÍѤ¤¤¿ÂçIJ´â´Îž°Ü¾ÉÎã¤ËÂФ¹¤ëưÃíÎÅË¡¤Î¸¡Æ¤ ¢¡Å¾°ÜÀ­´Î¡´â ¾
Gefitinib for Previously Untreated Patients with¡¡Non-Small Cell Lung Cancer (NSCLC) -A Retrospective Study of 12 Patients Treated in One Institution ¢¡È󾮺Ù˦´â ¾
Gefitinib(Iressa)¤¬ÁÕ¸ú¸åºÆÈ¯¤·¤¿È󾮺Ù˦ÇÙ´â¤Î3Îã ¢¡Ê¬»ÒɸŪÌô ¾
Gefitinib(Iressa)¤ÈÈ󾮺Ù˦ÇÙ´â ¢¡Ê¬»ÒɸŪÌô ¾
Gefitinib(Iressa)ÅêÍ¿¸å¤ËÇÙ˦½Ð·ì¤Ë¤è¤ëµÞÀ­¸ÆµÛÉÔÁ´¤òÍ褷¤¿ÇÙÁ£´â¤Î1Îã ¢¡È󾮺Ù˦´â ¾
Gefitinib¤¬Í­¸ú¤Ç¤¢¤Ã¤¿ÇÙÁ£´âž°Ü¤Ë¤è¤ë´âÀ­Ê¢Ëì±ê¤Î1Îã ¢¡ÇÙ´â ¾
Gefitinib¤ÎÅêÍ¿¤¬ÁÕ¸ú¤·¤¿ËýÀ­¿ÕÉÔÁ´¤È¸ÆµÛÉÔÁ´¤òȼ¤¦¸¶È¯À­ÇÙ´â½Ñ¸åºÆÈ¯¤Î1¾ÉÎã ¢¡£²·îÂ裳½µ¡§£±£¹Æü¡ÊÅÚ¡Ë Â¾
Gemcitabine Plus Cisplatin (GC)¡§A Salvage Regimen for Advanced Breast Cancer Patients Who Have Failed Anthracycline and/or Taxane Therapy33-06
Gemcitabine ¡Ý¤³¤ì¤«¤é¤ÎÆý´â¼£ÎÅÌô ¢¡8·îÂ裴½µ¡¡£²£¶Æü ¾
Gemcitabine+ÄãÍÑÎÌCDDP/5-FU¤òÍѤ¤¤¿Æ°Ãí²½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ËµÂçÆ°Ì®¥ê¥ó¥ÑÀឰܤòȼ¤¦¿Ê¹ÔÃÀǹ´â¤Î2Îã ¢¡ÃÀ´Îç¹ Â¾
Gemcitabine, DocetaxelÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯ÍñÁã´â¤Î2Îã ¢¡ÍñÁã´â ¾
Gemcitabine/CDDPÊ»ÍÑÎÅË¡¤¬ÁÕ¸ú¤·¤¿ç¯æṳ̀ʬ²½´â½Ñ¸åæþãÝ¥ê¥ó¥ÑÀឰܺÆÈ¯¤Î1Îã ¢¡ç¯æù´â ¾
Gemcitabine/CDDPÊ»ÍÑÎÅË¡¤Ë¤è¤êĹ´ü´ÖSD¤ò°Ý»ý¤·¤Æ¤¤¤ëÈóÀÚ½ü¿Ê¹ÔÃÀǹ´â¤Î1Îã ¢¡ÃÀÆ»´â ¾
Gemcitabine¡ÜVinorelbineÊ»ÍÑÎÅË¡¤¬Í­ÍѤǤ¢¤Ã¤¿¹âÎð¼ÔÈ󾮺Ù˦ÇÙ´â¤Î1Îã ¢¡È󾮺Ù˦´â ¾
Gemcitabine¤¬ÁÕ¸ú¤·¤¿ÀÚ½üÉÔǽ¿Ê¹Ôç¹´â¤Î1Îã ¢¡ç¹Â¡´â ¾
Gemcitabine¤ÇLong NC¤È¤Ê¤ê22¤«·î¤Î̵¾É¾õ³°ÍèÄ̱¡¤¬²Äǽ¤Ç¤¢¤Ã¤¿ÈóÀÚ½üç¹´â¤Î1Îã ¢¡²½³ØÎÅË¡ ¾
Gemcitabine¤ÈCisplatinÊ»ÍѲ½³ØÎÅË¡¤¬ÁÕ¸ú¤·¤¿ºÆÈ¯ÇÙ´â¤Î1Îã ¢¡ÇÙ´â ¾
Gemcitabine¤ÈVinorelbine¤ÎÊ»ÍѤ¬ÁÕ¸ú¤·¤¿80ºÐ¤ÎÀÚ½üÉÔǽÇÙÁ£´â¤Î1Îã ¢¡¶»Á£¼ð ¾
Gemcitabine¤Ë¤ÆQOL²þÁ±¤È±äÌ¿¤¬ÆÀ¤é¤ì¤¿¤ÓÌ¡À­°­À­¶»ËìÃæÈé¼ð¤Î1Îã ¢¡¶»Éô ¾
Gemcitabine¤Ë¤è¤ëç¹´â¤Î²½³ØÎÅË¡ ¢¡ç¹Â¡´â ¾
Gemcitabine¤ÎÉûºîÍѤȹͤ¨¤é¤ì¤ëËö¾¿À­Éâ¼ð¤ò¹çÊ»¤·¤¿¿Ê¹Ôç¹´â¤Î1Îã ¢¡Éâ¼ð ¾
Gemcitabine¤òÍѤ¤¤¿ç¹´â½Ñ¸åÊä½õÎÅË¡-°ÂÁ´À­¤È¼£ÎÅÀ®ÀÓ- ¢¡ç¹Â¡´â ¾
GemcitabineñÆÈÎÅË¡¤Ë¤è¤êTumor Dormancy¤ÎÆÀ¤é¤ì¤¿ÀÚ½üÉÔǽ繴â¤Î1Îã ¢¡ç¹Â¡´â ¾
GemcitabineÅêÍ¿¤Ë¤è¤ê´Îž°Ü¤¬¾Ã¼º¤·¤¿ç¹´â½Ñ¸å´Îž°ÜºÆÈ¯¤Î1Îã ¢¡ç¹Â¡´â ¾
GemcitabineÅêÍ¿¸å¤ÎÁýÂç¤ËÂФ·TS-1ñÆÈÅêÍ¿¤¬¸ú²ÌŪ¤Ç¤¢¤Ã¤¿¶É½ê¿Ê¹Ôç¹´â¤Î1Îã ¢¡2·îÂè4½µ ¾
GemcitabineưÃí¤¬ÁÕ¸ú¤·¤Æ¤¤¤ëç¹ÂÎÈøÉô´â¤Î1Îã ¢¡ç¹Â¡´â ¾
GERD¤Ë¹çÊ»¤·¤¿¿©Æ»ÆýƬ¼ð¤Î1Îã¡¡¡¦¡¦¡¦Ï¢¡¡ºÜ¡¡¡¡°ìÅ٤ߤ¿¤é˺¤ì¤é¤ì¤Ê¤¤Æâ»ë¶ÀÁü ¡¡¡¡¡¡ ­µ.¾ÉÎã¡¡83ºÐ¡¡½÷À­¡¡¹â·ì°µ¡¡¹â¡¦¡¦ ¢¡¿©Æ»´â ¾
GFPȯ¸½·Ï¤òÍѤ¤¤¿Ìȱ֥¨¥Õ¥§¥¯¥¿¡¼ºÙ˦¤ÎÀ¸ÂÎÆâÆ°Â֤θ¡Æ¤ ¢¡ÌȱÖÎÅË¡ ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤ËÂФ¹¤ëÊ¢¹Ð¶À²¼¼ê½Ñ¡½Å¬±þ¤ÈÊýË¡ ¢¡GIST ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤Î¸½¶· ¢¡GIST ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎͲ»ÇÈÆâ»ë¶À¿ÇÃÇ ¢¡GIST ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤Îɸ½àŪ¼ê½ÑÎÅË¡ ¢¡GIST ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎÌȱÖÁÈ¿¥²½³Ø¤Ë¤è¤ë¿ÇÃÇ ¢¡GIST ¾
GIST¡Êgastrointestinal stromal tumor¡Ë¤ÎÌôʪÎÅË¡ ¢¡GIST ¾
Granulocyte-colony stimulating factor»ºÀ¸Â¿È¯°ß´â¤Î1Îã39-04
H.pylori ÌôºÞ´¶¼õÀ­»î¸³Ë¡¡¡¡¦¡¦¡¦ÌôºÞ´¶¼õÀ­»î¸³¤Î¼ÂºÝ¡¡ H.pylori½ü¶ÝÎÅË¡¤Ë¤ª¤±¤ëCAM,AMPC¤Î¥Ö¥ì¥¤¥¯¥Ý¥¤¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡13C-Ç¢ÁǸƵ¤»î¸³Ë¡¡¡¡¦¡¦¡¦¸¶Íý¡¡ ¬Äê´ð½à¡¡ ·ë²Ì¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡·ìÀ¶¥Ú¥×¥·¥Î¥²¥óI/IIÈæ»î¸³ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡¹³ÂάÄêË¡¡¡¡¦¡¦¡¦·ìÀ¶¹³ÂάÄêË¡¡¡ Ç¢Ãæ¹³ÂάÄêË¡¡¡ ¹³ÂάÄêË¡¤ÎÌò³ä¡¡¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡½ü¶ÝÎÅË¡¤ÎŬ±þ¡¡¡¦¡¦¡¦½ü¶Ý¼£ÎŤ¬´«¤á¤é¤ì¤ë¼À´µ¡¡ ÀìÌç»ÜÀߤÇH.pylori½ü¶Ý¼£ÎŤ¬´«¤á¤é¤ì¤ë¼À´µ¡¡ H¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡¿·3ºÞÊ»ÍÑÎÅË¡¤ÎÍ­ÍÑÀ­¡¡¡¦¡¦¡¦¿·3ºÞÊ»ÍÑÎÅË¡¤È¥¬¥¤¥É¥é¥¤¥ó¡¡ ¸ú²Ì¡¡¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¡¡¡¦¡¦¡¦¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¤Î»ÔÈÎ¥­¥Ã¥È¡¡ ÆÃħ¡¡ ¿·¤·¤¤¿×®¥¦¥ì¥¢¡¼¥¼»î¸³¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡Æâ»ë¶À²¼À¸¸¡Ë¡¡¡¡¦¡¦¡¦H.pylori¶À¸¡Ë¡¤Î°ìÈÌÃí°Õ»ö¹à¡¡ H.pylori´¶À÷°ßÇ´Ëì¤Ëǧ¤á¤é¤ì¤ëÉÂÍýÁÈ¿¥¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori¡¡ÇÝÍܸ¡ºº¡¡¡¦¡¦¡¦H.pylori¤ÎÀ¸Êª²½³ØÅªÀ­¾õ¡¡ ¸¡ÂκμèË¡¡¢Êݸˡ¡¡ ÇÝÍÜË¡¤Î¼ÂºÝ¡¡ ÇÝÍÜË¡¤Î¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori´¶À÷¤ÈK-ras°äÅÁ»Ò¤Î´ØÍ¿ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori´¶À÷¾É¤ÎËÜË®±Ö³ØÅý·×¡¡¡¦¡¦¡¦Ìµ¾É¸õ¼Ô¤Ë¤ª¤±¤ëH.pylori¤Î´¶À÷Ψ¡¡ ¼À´µ¤È¤Î´Ø¤ï¤ê ¡¡ËýÀ­°à½ÌÀ­°ß±ê¡¡ ¡¡¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori½ü¶Ý¸å¤Î½ôÌäÂê¤ÈÂкö¡¡¡¦¡¦¡¦¤Ó¤é¤ó¡¡ÄÙáç¡¡¿©Æ»±ê¡¡¡¦¡¦¡¦¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori½ü¶Ý¼£ÎŸå¤Î´¶À÷¿ÇÃÇ¡¡¡¦¡¦¡¦µ¶ÍÛÀ­¡¦µ¶±¢À­¤Î¾¯¤Ê¤¤½ü¶ÝȽÄ꤬ɬÍפǤ¢¤ë¡£¡¡ ´¶À÷¿ÇÃÇË¡¤ÎÆÃħ¤òÃΤ롡 ½ü¶ÝȽÄê»þ¡¦¡¦ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori½ü¶Ý¼£ÎÅÉÔ±þÎã¤ÈºÆ½ü¶Ý¼£ÎŤÎÊýË¡ÏÀ ¢¡¥Ô¥í¥ê¶Ý ¾
H.pylori½ü¶ÝÎÅË¡¤Î¸½¾õ¤Èº£¸å¤ÎÌäÂêÅÀ- ÆÃ¤Ë°ß´â¤òÃæ¿´¤Ë¤·¤Æ ¢¡¥Ô¥í¥ê¶Ý ¾
HCV¥³¥¢°äÅÁ»Ò¥È¥é¥ó¥¹¥¸¥§¥Ë¥Ã¥¯¥Þ¥¦¥¹¤ò¥â¥Ç¥ë¤È¤¹¤ë´Îȯ´âµ¡½ø¤Î¹Í¤¨Êý ¢¡´Î±ê ¾
Heat shock protein70·ë¹çÃÁÇò¼Á(HspBP1)¤Î¥¢¥Ý¥È¡¼¥·¥¹Í¶Æ³Â¥¿Ê¸ú²Ì ¢¡Ê¬»ÒɸŪÌô ¾
Helicobacter pylori ½ü¶Ý¤ÎÌäÂêÅÀ ¢¡¥Ô¥í¥ê¶Ý ¾
Helicobacter pylori´¶À÷¤È´ØÏ¢¼À´µ ¢¡¥Ô¥í¥ê¶Ý ¾
Helicobacter pylori¶Ý¤È¥«¥ÓÆÇÁǤˤè¤ë°ßȯ´âµ¡¹½¤Ë´Ø¤¹¤ëºÇ¿·¸¦µæ ¢¡¥Ô¥í¥ê¶Ý ¾
helicobacter pylori½ü¶Ý¤Ë¤è¤ê¾ÃÂष¤¿´â²½²á·ÁÀ®À­°ß¥Ý¥ê¡¼¥×¤Î1Îã ¢¡¥Ô¥í¥ê¶Ý ¾
Helicobacter pylori½ü¶ÝȽÄê¤Ë¤ª¤±¤ë13C-Ç¢ÁǸƵ¤»î¸³¤ÎÍ­ÍÑÀ­¤ÈÌäÂêÅÀ ¢¡¥Ô¥í¥ê¶Ý ¾
Helicobaster pylori´¶À÷¤È°ß´â¤ÎÁÈ¿¥È¯À¸ ¢¡¥Ô¥í¥ê¶Ý ¾
HER-2/neuȯ¸½¡¦Trastuzumab»ÈÍѤÈǾž°Üȯ¾É¤È¤Î´ØÏ¢°ìž°Ü¡¦ºÆÈ¯Æý´â141ÎãÃæÇ¾Å¾°Ü38Îã¤Î²òÀϤ«¤é ¢¡Æý´â ¾
HER2²á¾êȯ¸½¤òÄ褹¤ëž°ÜÀ­Æý´â¤ËÂФ¹¤ëDocetaxel¤ÈTrastuzumab Ê»ÍÑÎÅË¡¤Î¸¡Æ¤ ¢¡£··îÂ裳½µ¡§£±£¶Æü¡ÊÅÚ¡Ë Â¾
Herceptin(R)¤È¼£ÎÅÀïά¡¡¡¦¡¦¡¦¥Ï¡¼¥»¥×¥Á¥ó¡¡¥Í¥ª¥¢¥¸¥å¥Ð¥ó¥ÈÎÅË¡¡¦¡¦ ¢¡Æý´â ¾
High¡¡Risk¹ü¿ñ°Û·ÁÀ®¾É¸õ·²¤ËÂФ¹¤ëÄãÍÑÎÌMelphalanÆâÉþÎÅË¡ ¢¡¹ü¿ñ°Û·ÁÀ®¾É¸õ·² ¾
HLA-A24¹´Â«À­HER2¥¨¥Ô¥È¡¼¥×ƱÄê¤È´â¥ï¥¯¥Á¥óÎÅË¡ ¢¡°ß´â ¾
HLA-A24¹´Â«À­HER2ͳÍèCTL¥¨¥Ô¥È¡¼¥×ƱÄê¤È´â¥ï¥¯¥Á¥óÎÅË¡ ¢¡ÌȱÖÎÅË¡ ¾
Hodgkin¥ê¥ó¥Ñ¼ð¤Îʬ»ÒÉÂÍý¡¡¡¦¡¦¡¦¿·¤·¤¤¥ê¥ó¥Ñ¼ð¤ÎʬÎप¤è¤Ó¼£ÎÅ HL¤Îʬ»Ò¥ì¥Ù¥ë¤Ç¤ÎÉÂÂ֤κǿ·Ã諤òÃæ¿´¤Ë²òÀâ¡£¡¡¡¦¡¦ ¢¡°­À­¥ê¥ó¥Ñ¼ð ¾
Homer¾É¸õ·²,²£³Ö¿À·ÐËãáڤȾåÂçÀÅÌ®¾É¸õ·²¤òÍ褷¤¿·ÛÉô¾å½Ä³Ö¸¶È¯¤Î¿À·Ð²ê¼ð¤Î1Æý»ùÎã ¢¡£¹·îÂ裵½µ¡Ê£³£°Æü¡Ë ¾
HPC-adriamycin¤Îç¯æùÆâÃíÆþÎÅË¡¤ËÊ»ÍѤ·¤¿¥Ï¥¤¥Ñ¡¼¥µ¡¼¥ß¥¢¤Ë¤è¤ê´°Á´´²²ò¤ò¤ß¤¿ç¯æù´â¾ÉÎã ¢¡ŽÊ޲ŽÊŽßް޻ްŽÐޱ¤ÎÎ×¾² ¾
HPLC¤Ë¤è¤ëUracil,Dihydrouracil,5-Fluorouracil¤ª¤è¤Ó5-Fluoro-5,6-DihydrouracilÇ»Å٤άÄê ¢¡²½³ØÎÅË¡ ¾
Human Orotate Phosphoribosyl Transferase¹³ÂΤκîÀ½¤È¤½¤Î±þÍÑ ¢¡²½³ØÎÅË¡ ¾
Hyperther­Ðia alone or with low dose of chemotherapy in treatment of advanced breast cancer:Caser eport. ¢¡15-Supplement¡¡­µ ¾
Ia´üFIGOʬÎà¤È¤½¤Î¼è¤ê°·¤¤¡¡¡Ý»ÒµÜðô´â ¢¡£¸·îÂè1½µ(£¶Æü¡Ë ¾
IFN/CsAÎÅË¡¡¡¡¦¡¦¡¦¥µ¥¤¥¯¥í¥¹¥Ý¥ê¥ó£Á¤È¥¦¥£¥ë¥¹À­´Î±ê¡¡ HCV°Ê³°¤Î¥¦¥£¥ë¥¹¤ËÂФ¹¤ë¥µ¥¤¥¯¥í¥¹¥Ý¥ê¥ó¤Î±Æ¡¦¡¦ ¢¡´Î±ê ¾
IFN/ribavirin¤ÎÊ»ÍѸú²Ì¡¡¡¦¡¦¡¦¥ê¥Ð¥Ó¥ê¥ó¤ÎºîÍѵ¡½ø¡¡ ¥ê¥Ð¥Ó¥ê¥ó¤ÎñÆÈÅêÍ¿¡¡ IFN¤È¥ê¥Ð¥Ó¥ê¥ó¤ÎÊ»ÍѸú²Ì¡¡¡¦¡¦ ¢¡´Î±ê ¾
IFN¼£ÎŸå̵¾É¸õÀ­¥­¥ã¥ê¥¢¤È¤Ê¤Ã¤¿C·¿ËýÀ­´Î±ê±ê ¢¡´Î±ê ¾
III´üÇÙ´â¤Î¼ê½ÑÀ®ÀÓ¤Èɾ²Á ¡ÝÇÙ´â¤Î³ÈÂç¼ê½Ñ¤È½Ì¾®¼ê½Ñ°ì¤½¤Îɾ²Á¤ÈŸ˾106-06
Imatinib¡¡¡¦¡¦¡¦¥¤¥Þ¥Á¥Ë¥Ö¡¦¡¦ ¢¡Ê¬»ÒɸŪÌô ¾
¡¡

¥Ú¡¼¥¸¤ÎÀèÆ¬¤ËÌá¤ë¡¡¡¡ 1¡¿10¤Ø¡¡ 2¡¿10¡¡ 3¡¿10¤Ø¡¡ 4¡¿10¤Ø¡¡ 5¡¿10¤Ø¡¡ 6¡¿10¤Ø¡¡ 7¡¿10¤Ø¡¡ 8¡¿10¤Ø¡¡ 9¡¿10¤Ø¡¡ 10¡¿10¤Ø¡¡

¡¡Ãøºî¸¢Ë¡¤Î´Ø·¸¾å¡¢Í½¹ð¤Ê¤¯Ê£¼Ì¥µ¡¼¥Ó¥¹¤òÄä»ß¤·¤¿¤êÃøºî¸¢ÎÁ¤ò²þÄꤹ¤ë¾ì¹ç¤¬Í­¤ê¤Þ¤¹¡£